Clinical trials: sponsored by Sinocelltech Ltd.
Wet Age-related Macular Degeneration
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody（SCT510A）
- Trial name
- NCT04564937
- Testing
- SCT510A
- Volunteers
- 66 people
- Sponsor
- Sinocelltech Ltd.
Head and Neck Squamous Cell Carcinoma
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody#SCT200#and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous…
- Trial name
- NCT03874741
- Testing
- SCT200
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia A
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
This study is a multi-center, open-label, extension trial to evaluate the safety, efficacy of SCT800 in long term prophylaxis and on-demand treatment in patients with severe hemophilia A who have been previously treated with…
- Trial name
- NCT03947567
- Testing
- Recombinant Human Coagulation FVIII
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sinocelltech Ltd.
Head and Neck Cancer
Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma after failure of…
- Trial name
- NCT03713372
- Testing
- Anti-EGFR monoclonal antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia A
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
This study is a multi-center, open-label, single-arm trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (≥12 years old) with severe hemophilia A who…
- Trial name
- NCT03815318
- Testing
- Recombinant Human Coagulation FVIII
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Sinocelltech Ltd.
Head and Neck Squamous Cell Carcinoma
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma
- Trial name
- NCT04146402
- Testing
- SCT-I10A+chemo
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Esophageal Squamous Cell Carcinoma, Colorectal Cancer
Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
The purpose of this study is to evaluate the safety and efficacy of SCT-I10A combined SCT200 or SCT-I10A combined SCT200 plus chemotherapy in advanced esophageal squamous cell carcinoma and colorectal cancer
- Trial name
- NCT04229537
- Testing
- SCT-I10A, SCT200, Chemotherapy
- Volunteers
- 60 people
- Sponsor
- Sinocelltech Ltd.
Head and Neck Squamous Cell Carcinoma
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of SCT-I10A for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma who progressed on or after platinum-based chemotherapy
- Trial name
- NCT04146181
- Testing
- PD-1
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia A
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe…
- Trial name
- NCT03947320
- Testing
- Recombinant Human Coagulation FVIII
- Volunteers
- 70 people
- Sponsor
- Sinocelltech Ltd.
Advanced Solid Tumors or Lymphoma
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma…
- Trial name
- NCT03821363
- Testing
- SCT-I10A
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sinocelltech Ltd.
Esophageal Squamous Cell Carcinoma
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced esophageal squamous cell carcinoma progressed following treatment with…
- Trial name
- NCT03817567
- Testing
- recombinant anti-EGFR monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Advanced Squamous Non-small Cell Lung Cancer
Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced squamous non-small cell lung cancer treated after failure of Two chemotherapy regimens…
- Trial name
- sNSCLC (NCT03808701)
- Testing
- SCT200
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Non-squamous Cell Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic…
- Trial name
- NCT03792074
- Testing
- SCT510, Bevacizumab, Paclitaxel
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
Triple Negative Breast Neoplasms
Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with triple receptor negative breast cancer treated after failure of standard therapy (including…
- Trial name
- NCT03692689
- Testing
- SCT200
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sinocelltech Ltd.
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR monoclonal antibody（SCT200）in patients with advanced solid tumors treated after failure of standard therapy.
- Trial name
- NCT03692520
- Testing
- SCT200
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sinocelltech Ltd.
Metastatic Colorectal Cancer
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR Monoclonal antibody（SCT200）in patients with wild-type RAS and BRAF mCRC treated with fluorouracil, oxaliplatin and irinotecan after failure…
- Trial name
- NCT03405272
- Testing
- Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
- Where
- 21 sites in China
- Volunteers
- 110 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia A
Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A
In this trial safety and efficacy of SCT800 (B-domain deleted recombinant factor VIII) is being evaluated in 50 subjects, 12 to 65 years of age, with moderate to severe Hemophilia A.
- Trial name
- NCT02921945
- Testing
- SCT800
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia A
Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
Participants will be assigned to A or B groups with a scale of 1:1 based on a prospectively randomized treatment-sequence assignment, i.e. infuse SCT800 followed by Xyntha (group A), or the alternate sequence (group B).
- Trial name
- NCT02888223
- Testing
- SCT800, Xyntha
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sinocelltech Ltd.
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.
- Trial name
- NCT02772822
- Testing
- SCT400 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
B-cell Non Hodgkin's Lymphoma
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
The primary objective of the study is to assess the pharmacokinetic (PK) similarity of SCT400 versus rituximab (MabThera®) in patients with CD20+ B-cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT02456207
- Testing
- SCT400, Rituximab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sinocelltech Ltd.